Modalis Therapeutics Corporation
4883・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 6 members in total (1 Representative Director and President, 2 outside directors, and 3 outside directors who are Audit and Supervisory Committee members), with an outside director ratio of 5/6 (approximately 83%). The Board of Directors met 19 times during the fiscal year under review (with full attendance). The establishment of a Nomination Committee or Compensation Committee is not confirmed in the Annual Securities Report.
Risk Management
The Company has established the "Risk Management Regulations" to build a system for early identification and sharing of risk information. A Compliance Committee, chaired by the Representative Director and President, has been set up to deliberate on legal compliance, and through collaboration with external experts in law, patents, accounting, and other fields, as well as the operation of an internal whistleblowing system, the Company works to prevent risks from materializing and to detect and correct misconduct at an early stage.
Shareholder Returns
No dividends have been paid since the company's founding. The annual dividend is ¥0.00 for both FY2025 (ending December 2025) and FY2026 (ending December 2026). The company plans to prioritize securing research and development funding for the time being and will not implement dividends. No share buybacks or shareholder benefit programs are in place either.
Dividend Policy
The company has not paid dividends since its founding, and since it plans to systematically carry out research and development activities that involve substantial upfront investment, it will prioritize securing R&D funding rather than paying dividends for the time being. In the future, if the company becomes able to generate stable earnings and secure sufficient profit to cover R&D funding needs, it will consider profit distribution after comprehensively taking into account factors such as the need to strengthen internal reserves. If dividends are paid, the company envisions two payments per year—an interim dividend and a year-end dividend—with the decision made by the Board of Directors. The forecast annual dividend for FY2026 (ending December 2026) is ¥0.00 (¥0.00 at the second-quarter end, ¥0.00 at year-end).
ESG
Under the corporate philosophy of "Every life deserves attention," the company aims to contribute to society through the development of gene disease therapeutics utilizing CRISPR-GNDM® technology. In terms of human capital, the company has established a flextime system, stock option system, and a post-delivery type stock compensation system, and provides employee training; however, quantitative ESG indicators and targets have not yet been set, and the company is currently considering whether such targets should be established going forward.
Last updated: March 25, 2026